{"id":"nct:NCT03814187","kind":"trial","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2019,"published":"2019-01-23","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT03814187","source_url":"https://clinicaltrials.gov/study/NCT03814187","archive_url":"https://space-kitty.com/papers/nct:NCT03814187","updated":"2024-03-06","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["ASCVD","Elevated Cholesterol","Heterozygous Familial Hypercholesterolemia","Homozygous Familial Hypercholesterolemia"],"details":{"acronym":"ORION-8","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":3275,"sponsor":"Novartis Pharmaceuticals","conditions":["ASCVD","Elevated Cholesterol","Heterozygous Familial Hypercholesterolemia","Homozygous Familial Hypercholesterolemia"],"interventions":["DRUG: Inclisiran Sodium"],"start_date":"2019-04-16","start_date_type":"ACTUAL","primary_completion_date":"2023-02-13","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}